New drugs for exacerbations of chronic obstructive pulmonary disease : The Lancet
Links shared publicly online about this topic.
- 1,780total visits
New drugs for exacerbations of chronic obstructive pulmonary disease : The Lancet
View full resource at thelancet.com
Tags: COPD, Disease and Condition, Drug, Pulmonology
Most Recently Shared on September 1, 2009 at 10:28 pm By:
New drugs for #COPD exacerbations - http://bit.ly/nFzSg
Tiotropium superior to salmeterol in preventing exacerbations in COPD - - Drug Topics
drugtopics.modernmedicine.com — “The anticholinergic drug tiotropium is more effective than the ?2-agonist salmeterol in preventing exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease, according to a multi-center European study published in the New England Journal of Medicine.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on April 9, 2011 at 2:24 am By:
Drugs and Devices OW OW Health
Tiotropium superior to salmeterol in preventing exacerbations in COPD: The anticholinergic drug tiotropium is mo... http://bit.ly/e7E9FM
Tiotropium Outperforms Salmeterol in Moderate COPD - Physician's First Watch
firstwatch.jwatch.org — “The anticholinergic drug tiotropium is more effective at forestalling exacerbations in chronic obstructive pulmonary disease than the beta-2 agonist salmeterol, according to a New England Journal of Medicine study. International researchers (including employees of tiotropium's . . . LINK(S):” View full resource at firstwatch.jwatch.org
Most Recently Shared on March 25, 2011 at 1:17 am By:
Lionel Lim Internist, Geriatrician, Physician, and Doctor
Tiotropium Outperforms Salmeterol in Moderate COPD - http://icio.us/PNudqL
N30 Pharma Announces FDA Approval To Initiate Phase 1 Clinical Trial For First-in-Class Drug - QualityPoint Technologies
qualitypointtech.net — “N30 Pharmaceuticals, LLC announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD). N30 Pharma will now begin a first-in-man, Phase 1, dose escalation trial of N6022 in healthy subjects...” View full resource at qualitypointtech.net
Most Recently Shared on August 5, 2010 at 3:48 pm By:
N30 Pharma Announces FDA Approval To Initiate Phase 1 Clinical Trial For First-in-Class Drug: N30 Pharmaceuticals,... http://bit.ly/dlwMLG
Advertisement
